A federal judge in Massachusetts has denied Eli Lilly and Co.’s motion to dismiss a lawsuit filed by its competitor Teva Pharmaceutical, allowing a patent dispute over migraine prevention treatment to continue.
Teva argues that Eli Lilly induced infringement of two of Teva’s patents—11,028,160 and 11,028,161, titled “Treating Refractory Migraines”—which protect the methods for administering the drug for the treatment of “refractory” migraines, or for patients who failed on at least two prior migraine preventative treatments.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
